Kymera Therapeutics, Inc. - COMMON STOCK (KYMR)

CUSIP: 501575104

Q3 2023 13F Holders as of 30 Sep 2023

Holder snapshot 7 signals
Share change
-1,082,917
Put/Call ratio
13%
SEC-reported price per share
$13.90
Number of holders
120
Value change
-$18,249,775
Number of buys
60
Open additional details 1 more signal available
Number of sells
53
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
82,930,729

Security key

501575104

Report period

Q3 2023

Institutions

120

Top holders

10

Ownership snapshot

Top reported holders of KYMR - Kymera Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ATLAS VENTURE ASSOCIATES ...
Disclosed value leader
ATLAS VENTURE ASSOCIATES ...
Comparable rows
0/15
Latest evidence
30 Jun 2023
3/4/5 13F Highest disclosed value: $173,161,222 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

ATLAS VENTURE ASSOCIATES X, L.P. has the largest disclosed position value at $173.16M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ATLAS VENTURE ASSOCIATES X, L.P.'s linked filing trail.
Disclosed position value Top 5
ATLAS VENTURE ASSOCIATES X, L.P. $173.16M
Atlas Venture Life Science Adviso... $134.68M
PRICE T ROWE ASSOCIATES INC /MD/ $115.12M
WELLINGTON MANAGEMENT GROUP LLP $110.87M
BVF INC/IL $108.95M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ATLAS VENTURE ASSOCIATES X, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$173,161,222
5,763,012 shares
— 11 Aug 2021
Atlas Venture Life Science Advisors, LLC
13F
Company
13F
—
denominator unverified
$134,681,443
5,858,262 shares
— 30 Jun 2023
PRICE T ROWE ASSOCIATES INC /MD/
13F
Company
13F
—
denominator unverified
$115,115,000
5,007,148 shares
— 30 Jun 2023
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
13F
—
denominator unverified
$110,873,482
4,822,683 shares
— 30 Jun 2023
BVF INC/IL
13F
Company
13F
—
denominator unverified
$108,949,702
4,739,004 shares
— 30 Jun 2023
BAKER BROS. ADVISORS LP
13F
Company
13F
—
denominator unverified
$100,589,067
4,375,340 shares
— 30 Jun 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
120
Shares
57,350,132
Rows available
120
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 holders
124
Q3 2023 holders
120
Holder diff
-4
Investor Q2 2023 Shares Q3 2023 Shares Share Diff Share Chg % Q2 2023 value Q3 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .